Primary Immune Thrombocytopenia in Pregnancy: Pathology, Diagnosis, and Management

Authors' Contributions

J. L. wrote the paper, L. Z. read and approved the final manuscript.

Funding

This work was supported by grants from the National Key Research and Development Program of China (2019YFA0110802), CAMS Innovation Fund for Medical Sciences (CIFMS, 2022-I2M-2-003), and Haihe Laboratory of Cell Ecosystem Innovation Fund (22HHXBSS00022).

Conflict of Interest

None declared.

References

[1] Liu XG, Hou Y, Hou M. How we treat primary immune thrombocytopenia in adults. J Hematol Oncol 2023;16(01):4

[2] Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood 2014;124(22):3308-3315

[3] Lee JY, Lee JH, Lee H, et al. Epidemiology and management of primary immune thrombocytopenia: a nationwide populationbased study in Korea. Thromb Res 2017;155:86-91

[4] Obstetrics Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Expert consensus on diagnosis and treatment of primary immune thrombocytopenia in pregnancy [in Chinese]. Zhonghua Fu Chan Ke Za Zhi 2023;58(03): 170-177

[5] Zhang X, Zhao Y, Li X, et al. Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy. Oncotarget 2016;7(07):7489-7496

[6] Frölich MA, Datta S, Corn SB. Thrombopoietin in normal pregnancy and preeclampsia. Am J Obstet Gynecol 1998;179(01): 100-104

[7] Dupuis M, Severin S, Noirrit-Esclassan E, Arnal JF, Payrastre B, Valéra MC. Effects of estrogens on platelets and megakaryocytes. Int J Mol Sci 2019;20(12):3111

[8] Bussel JB, Hou M, Cines DB. Management of primary immune thrombocytopenia in pregnancy. N Engl J Med 2023;389(06): 540-548

[9] Reese JA, Peck JD, Deschamps DR, et al. Platelet counts during pregnancy. N Engl J Med 2018;379(01):32-43

[10] Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019;3(22):3780-3817

[11] Cines DB, Levine LD. Thrombocytopenia in pregnancy. Blood 2017;130(21):2271-2277

[12] Guillet S, Loustau V, Boutin E, et al. Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study. Blood 2023;141(01):11-21

[13] Lee LO, Bateman BT, Kheterpal S, et al; Multicenter Perioperative Outcomes Group Investigators. Risk of epidural hematoma after neuraxial techniques in thrombocytopenic parturients: a report from the multicenter perioperative outcomes group. Anesthesiology 2017;126(06):1053-1063

[14] Michel M, Ruggeri M, Gonzalez-Lopez TJ, et al. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood 2020;136(26): 3056-3061

[15] Bussel JB, Cooper N, Lawrence T, et al. Romiplostim use in pregnant women with immune thrombocytopenia. Am J Hematol 2023;98(01):31-40

[16] Agarwal N, Mangla A. Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review. Ther Adv Hematol 2021;12:20406207211001139

[17] Howaidi J, AlRajhi AM, Howaidi A, AlNajjar FH, Tailor IK. Use of thrombopoietin receptor agonists in pregnancy: a review of the literature. Hematol Oncol Stem Cell Ther 2022;15(01):1-6

[18] Purushothaman J, Puthumana KJ,Kumar A, Innah SJ, Gilvaz S. A case of refractory immune thrombocytopenia in pregnancy managed with elthrombopag. Asian J Transfus Sci 2016;10(02):155-158

RIGHTS & PERMISSIONS

Global Medical Genetics